Small Specialty Pharma Merus Reviews Strategy Amid Sector Woes
Canada’s Merus Labs has recruited Rothschild & Co to review its business strategy, as much larger companies in the specialty market sector retrench with asset sales and job cuts.
You may also be interested in...
Merus Labs' portfolio of well-established products are mainly marketed in Europe, and will drive the growth and diversification of Norgine’s specialty business in the region.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Perrigo bows to pressure from activist investor to 'unlock value' by selling Tysabri royalty stream and laying off 750 staff, but still provides a weak outlook for 2017, prompting analysts to question the wisdom of the strategy.